Thompson Travis Alvin 4

What Happened

• Travis Alvin Thompson, Chief Financial Officer of Bicycle Therapeutics plc (BCYC), received a derivative equity award of 58,000 shares on February 3, 2026. The filing reports a $0.00 price for the grant and classifies the transaction as an award/grant (transaction code A). The award is described in the filing footnote as an option.

Key Details

• Transaction date: 2026-02-03; SEC filing date: 2026-02-04 (appears timely).
• Transaction type/code: Award/Grant (A) — reported as a derivative.
• Quantity and price: 58,000 shares; $0.00 per share reported; filing lists total value as $0.
• Shares owned after transaction: Not specified in the provided filing details.
• Vesting schedule (footnote): 25% of the option vests on February 3, 2027; remaining shares vest in 36 equal monthly installments thereafter (i.e., roughly a four-year vesting profile: 1-year cliff then monthly over 3 years).
• No sale, exercise, tax-withholding, or 10b5-1 plan disclosed in this filing.

Context

• This was a compensation grant (an option award) rather than an open-market purchase or sale. It does not represent an immediate cash investment or disposition by the insider. Grants are routine elements of executive compensation and do not by themselves indicate the insider’s near-term trading intent or a bullish/bearish signal.